leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 22:16:50 - browse：64

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Arc Institute generative AI designs new CRISPR systems

Wikipedia

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

NVIDIA and Google execs on the future of AI and drug discovery

John Green on his newest strategy for fighting tuberculosis

President Biden's budget: Here's what you might have missed

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

How many hemophilia patients actually want gene therapy?

leisure time

leisure time

leisure time

Medical leaders decry Supreme Court decision on affirmative action

NVIDIA and Google execs on the future of AI and drug discovery

At least 13 dead in Texas as scorching temps continue

Boston's new lab space is opening empty

Drug repurposing or repositioning? The language matters

Case highlights the risks of experimental stem cell therapy

23andMe had bad news about my health. I wish a person had delivered it

HIV vaccine remains elusive. Immunologists keep trying new ideas

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

explore

Helping hospitals and community health centers plan for resilience

President Biden's budget: Here's what you might have missed

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Why depression after traumatic brain injury is distinct

How many hemophilia patients actually want gene therapy?

Readers respond to H5N1 and livestock movements, and more

focus

Wikipedia

knowledge

leisure time